Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation

Journal of Cardiovascular Electrophysiology

Volumn 22, Issue 3, 2011, Pages 316-324

  Alcalai, Ronny ^a,b   Wakimoto, Hiroko ^a,e   Arad, Michael ^c   Planer, David ^b   Konno, Tetsuo ^a   Wang, Libin ^a   Seidman, Jon G ^a   Seidman, Christine E ^d   Berul, Charles I ^e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

antiarrhythmia agents; calcium; calsequestrin 2; CPVT; mouse model; sudden death

Indexed keywords

CALCIUM BINDING PROTEIN; CALCIUM ION; CALSEQUESTRIN 2; DILTIAZEM; MAGNESIUM; PROPRANOLOL; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; DRUG BLOOD LEVEL; DRUG EFFICACY; GENE MUTATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE ARRHYTHMIA; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; CALSEQUESTRIN; DILTIAZEM; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; GENE KNOCK-IN TECHNIQUES; MAGNESIUM; MICE; MICE, KNOCKOUT; MUTATION; MYOCYTES, CARDIAC; PROPRANOLOL; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; TACHYCARDIA, VENTRICULAR; TIME FACTORS; VERAPAMIL;

EID: 79952509642     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2010.01877.x     Document Type: Article

References (40)

1. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA,: Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200. (Pubitemid 32095402)
2. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K,: Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103: 485-490. (Pubitemid 32116230)
3. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M,: A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378-1384. (Pubitemid 33124218)
4. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, Mannens MM, Wilde AA, Guicheney P,: Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91: e21-e6.
5. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P,: Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512-1519.
6. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A, Lorber A, Kastner DL, Goldman B, Pras E,: Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: Clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103: 2822-2827. (Pubitemid 32550071)
7. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A,: Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74. (Pubitemid 34747444)
8. Liu N, Ruan Y, Priori SG,: Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis 2008; 51: 23-30. (Pubitemid 351965496)
9. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A,: Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119: 2426-2434.
10. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, Saito A, Kurosaki K, Jouo K, Koujiro M, Konishi S, Matsuoka S, Oono T, Hayakawa S, Miura M, Ushinohama H, Shibata T, Niimura I,: Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70. (Pubitemid 36044293)
11. Swan H, Laitinen P, Kontula K, Toivonen L,: Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005; 16: 162-166. (Pubitemid 40326272)
12. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC,: Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380-383.
13. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, Ferrandi C, Koolbergen DR, Odero A, Schwartz PJ,: Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008; 358: 2024-2029. (Pubitemid 351656456)
14. Atallah J, Fynn-Thompson F, Cecchin F, DiBardino DJ, Walsh EP, Berul CI,: Video-assisted thoracoscopic cardiac denervation: A potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg 2008; 86: 1620-1625.
15. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K, Knollmann BE, Horton KD, Weissman NJ, Holinstat I, Zhang W, Roden DM, Jones LR, Franzini-Armstrong C, Pfeifer K,: Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2006; 116: 2510-2520. (Pubitemid 44330150)
16. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, Napolitano C, Priori SG,: Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 2005; 96: e77-e82.
17. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG,: Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: Insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006; 99: 292-298. (Pubitemid 44174937)
18. Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, Landry DW, Kontula K, Swan H, Marks AR,: Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 2004; 109: 3208-3214.
19. George CH, Higgs GV, Lai FA,: Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 2003; 93: 531-540. (Pubitemid 37163233)
20. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F, Valle G, Rizzi N, Napolitano C, Gyorke S, Volpe P, Priori SG,: Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006; 114: 1012-1019. (Pubitemid 44358877)
21. Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, Berul CI, Eldar M, Seidman CE, Seidman JG,: Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2007; 117: 1814-1823. (Pubitemid 47036315)
22. Heilmann C, Brdiczka D, Nickel E, Pette D,: ATPase activities, Ca2+ transport and phosphoprotein formation in sarcoplasmic reticulum subfractions of fast and slow rabbit muscles. Eur J Biochem 1977; 81: 211-222. (Pubitemid 8241297)
23. Stoscheck CM,: Quantitation of protein. Methods Enzymol 1990; 182: 50-68. (Pubitemid 20154379)
24. Berul CI, Aronovitz MJ, Wang PJ, Mendelsohn ME,: In vivo cardiac electrophysiology studies in the mouse. Circulation 1996; 94: 2641-2648. (Pubitemid 26403597)
25. Gehrmann J, Berul CI,: Cardiac electrophysiology in genetically engineered mice. J Cardiovasc Electrophysiol 2000; 11: 354-368. (Pubitemid 30165357)
26. Lim CC, Apstein CS, Colucci WS, Liao R,: Impaired cell shortening and relengthening with increased pacing frequency are intrinsic to the senescent mouse cardiomyocyte. J Mol Cell Cardiol 2000; 32: 2075-2082.
27. Nagata K, Liao R, Eberli FR, Satoh N, Chevalier B, Apstein CS, Suter TM,: Early changes in excitation-contraction coupling: Transition from compensated hypertrophy to failure in Dahl salt-sensitive rat myocytes. Cardiovasc Res 1998; 37: 467-477. (Pubitemid 28166006)
28. Shannon TR, Ginsburg KS, Bers DM,: Quantitative assessment of the SR Ca2+ leak-load relationship. Circ Res 2002; 91: 594-600.
29. Viatchenko-Karpinski S, Terentyev D, Gyorke I, Györke I, Terentyeva R, Volpe P, Priori SG, Napolitano C, Nori A, Williams SC, Györke S,: Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. Circ Res 2004; 94: 471-477. (Pubitemid 38326282)
30. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, Viskin S,: Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 1149-1154. (Pubitemid 47324118)
31. Nam GB, Burashnikov A, Antzelevitch C,: Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 2005; 111: 2727-2733. (Pubitemid 40791542)
32. Romani A, Scarpa A,: Hormonal control of Mg2+ transport in the heart. Nature 1990; 346: 841-844.
33. Laver DR, Baynes TM, Dulhunty AF,: Magnesium inhibition of ryanodine-receptor calcium channels: Evidence for two independent mechanisms. J Membr Biol 1997; 156: 213-229. (Pubitemid 27208424)
34. Kong H, Jones PP, Koop A, Zhang L, Duff HJ, Chen SR,: Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor. Biochem J 2008; 414: 441-452.
35. Stevens SC, Terentyev D, Kalyanasundaram A, Periasamy M, Gyorke S,: Intra-sarcoplasmic reticulum Ca2+ oscillations are driven by dynamic regulation of ryanodine receptor function by luminal Ca2+ in cardiomyocytes. J Physiol 2009; 587 (Pt 20): 4863-4872.
36. Yano K, Zarain-Herzberg A,: Sarcoplasmic reticulum calsequestrins: Structural and functional properties. Mol Cell Biochem 1994; 135: 61-70. (Pubitemid 24279108)
37. Szegedi C, Sarkozi S, Herzog A, Jona I, Varsanyi M,: Calsequestrin: More than 'only' a luminal Ca2+ buffer inside the sarcoplasmic reticulum. Biochem J 1999; 337 (Pt 1): 19-22. (Pubitemid 29039077)
38. Terentyev D, Kubalova Z, Valle G, Nori A, Vedamoorthyrao S, Terentyeva R, Viatchenko-Karpinski S, Bers DM, Williams SC, Volpe P, Gyorke S,: Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: Effects of CASQ2 mutations linked to sudden cardiac death. Biophys J 2008; 95: 2037-2048.
39. Valdivia HH, Valdivia C, Ma J, Coronado R,: Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum. Biophys J 1990; 58: 471-481. (Pubitemid 20249674)
40. Nanda U, Ashish A, Why HJ,: Modified release verapamil induced cardiogenic shock. Emerg Med J 2005; 22: 832-833. (Pubitemid 41644808)